Dr. Weber received his M.D. from New York University and his Ph.D. from the Rockefeller University, and he completed a fellowship in medical oncology at the National Cancer Institute. Dr. Weber’s areas of interest include the use of vaccines and biologic compounds to treat melanoma, specifically antibodies against immune regulatory molecules and cytokine vaccine adjuvants. Recent clinical trials for which he is the principal investigator have included the use of multi-peptide vaccines with PD-1 antibody for patients with metastatic and resected melanoma, PD-1 antibody with CTLA-4 antibody and selective HDAC inhibition for patients with metastatic melanoma, and the use of TRAIL-R2 agonistic agents to augment apoptosis and deplete myeloid-derived suppressor cells in stage IV melanoma. He was also Professor and Associate Chair in the Department of Oncologic Sciences at the University of South Florida. Dr. Weber has been a clinical trialist and translational investigator for over 25 years and is an expert in cancer immunotherapy and melanoma research.Jeffrey S. Weber, M.D., Ph.D. is Deputy Director of the Laura and Isaac Perlmutter Cancer Center and Professor of Medicine at NYU Langone Medical Center, Co-director of its Melanoma Program and its Head of Experimental Therapeutics. Dr. Weber was previously Director of the Donald A. Adam Comprehensive Research Center and Senior Member at Moffitt Cancer Center. 

Oncology Immunology